SK Holdings, the parent company of South Korea’s third-largest conglomerate SK Group, announced that it has acquired a 100 percent stake in AMPAC Fine Chemicals, a US-based contract manufacturer of APIs.
Scientists at the Harvard John A. Paulson School of Engineering and Applied Sciences have developed an oral delivery method that could dramatically transform the way in which diabetics keep their blood sugar levels in check.
Celltrion signed an agreement with Yonsei University Health System on the joint development of Fc-Saxatilin, a candidate drug for ischemic strokes in a bid to develop new biopharmaceuticals for cerebrovascular diseases.
Eligo Bioscience, the French microbiome company, has secured a $20 million Series A round of financing from Khosla Ventures and Seventure Partners, including a $2 million award from the Worldwide Innovation Challenge.
CERENIS Therapeutics, an international biopharmaceutical company dedicated to the development of HDL-based innovative therapies, signed a strategic partnership with the University of North Texas Health Science Center.
Evox Therapeutics, a leading exosome therapeutics company, announced it has expanded into a new laboratory and office space at The Oxford Science Park, to enhance its research and development (R&D) capabilities.
Sandoz, a Novartis division and global leader in generic pharmaceuticals and biosimilars, entered into a collaboration with Pear Therapeutics to commercialize and continued development of novel prescription digital therapeutics.
According to leading data and analytics company GlobalData, large pharma firms are eager to collaborate with biotech companies and academic labs to further the development of microbiome-targeted therapeutics in immunology,
Arbutus Biopharma Corporation and Roivant Sciences entered into an agreement to launch Genevant Sciences, a company focused on the discovery, development, and commercialization of a broad range of RNA-based therapeutics.